Using monoclonal antibodies to prevent migraines in real-world settings
Non-interventional Study of the Austrian Headache Society: Monoclonal CGRP Antibodies for Migraine Prevention a Nationwide Real Life Study
Austrian Migraine Registry Collaboration · NCT05281770
This study is testing whether monoclonal antibodies can safely help people with migraines feel better in everyday life and how switching between different treatments affects them.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Austrian Migraine Registry Collaboration (network) |
| Drugs / interventions | erenumab, fremanezumab, galcanezumab, Eptinezumab |
| Locations | 3 sites (Innsbruck, Tirol and 2 other locations) |
| Trial ID | NCT05281770 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the safety and efficacy of monoclonal CGRP antibodies, such as erenumab, galcanezumab, and fremanezumab, for preventing migraines in a real-world population. It aims to gather data on long-term outcomes and the effects of switching between different CGRP therapies. The study will include patients with episodic or chronic migraines, both with and without aura, who are receiving these treatments as prescribed by their physicians. By focusing on a broader patient population, the study seeks to address gaps in existing clinical trial data.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with episodic or chronic migraines who are prescribed CGRP monoclonal antibodies as part of their standard care.
Not a fit: Patients who are not experiencing migraines or those receiving off-label use of CGRP antibodies will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the long-term safety and effectiveness of CGRP antibodies for migraine prevention in diverse patient populations.
How similar studies have performed: While previous studies have shown efficacy in controlled environments, this study is novel in its focus on real-world data and long-term outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria (all of the follwing) * episodic or chronic migraine with or without aura * erenumab, fremanezumab or galcanezumab is prescribed as a standard of care treatment by treating physician Eptinezumab may be included as soon as available in Austria. Exclusion Criteria: • Off label use of erenumab, fremanezumab or galcanezumab
Where this trial is running
Innsbruck, Tirol and 2 other locations
- Medical University Innsbruck — Innsbruck, Tirol, Austria (RECRUITING)
- Medizinische Universität Wien — Wien, Vienna, Austria (RECRUITING)
- Clinic Hietzing — Vienna, Austria (RECRUITING)
Study contacts
- Principal investigator: Gregor Broessner, Prof — Medical University Innbruck
- Study coordinator: Franz Riederer, Prof
- Email: franz.riederer@uzh.ch
- Phone: +436803279153
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Migraine, Migraine With Aura, Migraine Without Aura, Chronic Migraine, Episodic Migraine, Erenumab, Galcanezumab, Fremanezumab